Clinical data | |
---|---|
Trade names | Velsipity |
Other names | APD334, APD-334 |
License data | |
Routes of administration | By mouth |
Drug class | Sphingosine-1-phosphate receptor modulator |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 97.9% |
Metabolism | Liver (CYP2C8, 2C9, 3A4) |
Elimination half-life | 30 hours |
Excretion | Feces (82%), kidneys (5%) |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
DrugBank |
|
ChemSpider | |
UNII |
|
KEGG | |
ChEBI | |
ChEMBL | |
Chemical and physical data | |
Formula | C26H26F3NO3 |
Molar mass | 457.493 g·mol−1 |
3D model (JSmol) | |
| |
|
Etrasimod, sold under the brand name Velsipity, is a medication that is used for the treatment of ulcerative colitis (UC).[1] It is a selective sphingosine-1-phosphate (S1P) receptor modulator that modifies the activity of the immune system.[1] It is taken by mouth.[1]
Etrasimod was discovered by Arena Pharmaceuticals, with subsequent development by Pfizer.[2]
Etrasimod is used for the treatment of moderate to severe ulcerative colitis.[1]
It works by causing T cells to become trapped in the lymph nodes, preventing them from entering the bloodstream, from where they would travel to other tissues in the body and mediate inflammation.[3][4][5][6][7][8]
Velsipity was approved by the US Food and Drug Administration (FDA) in October 2023.[1][9][10]
In December 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Velsipity, intended for the treatment of ulcerative colitis.[11] The applicant for this medicinal product is Pfizer Europe MA EEIG.[11]
Etrasimod is the international nonproprietary name.[12]